Bcr Antibody (4C12): sc-53178

Bcr Antibody (4C12) is a mouse monoclonal IgG1 kappa light chain antibody, raised against a Bcr-Abl-Abl peptide, and is designed to recognize the human Bcr protein. The Bcr protein, also known as Breakpoint Cluster Region protein or Renal carcinoma antigen NY-REN-26, is essential for regulating cellular signaling pathways by functioning as a GTPase-activating protein (GAP) for Rac1 p21. This regulation is crucial for controlling cytoskeletal dynamics, cell migration, and proliferation. Structurally, Bcr contains multiple domains, including the GAP domain, which is vital for its interaction with Rac1 and the modulation of its activity. Post-translational modifications, such as phosphorylation, play a significant role in modulating Bcr′s function and its interactions with other proteins, thereby influencing key cellular processes related to growth and survival. The Bcr gene, located on chromosome 22, is prominently involved in the formation of the Philadelphia chromosome through a translocation with the c-Abl proto-oncogene on chromosome 9, a genetic event present in approximately 90-95% of chronic myelogenous leukemia (CML) cases. This translocation results in the production of the Bcr/Abl fusion protein, which possesses constitutive tyrosine kinase activity, leading to the uncontrolled proliferation of leukemic cells. Anti-Bcr antibody (4C12) effectively detects the Bcr protein in human samples and is optimized for use in immunofluorescence (IF) applications. By enabling the precise detection and analysis of Bcr and its fusion proteins, Bcr (4C12) antibody serves as an invaluable tool for researchers investigating the molecular mechanisms underlying CML and other related diseases.

The preferred c-Abl antibody is c-Abl Antibody (24-11): sc-23.